Seaport Therapeutics, a Boston biotech led by Daphne Zohar, has filed to go public, setting up a Nasdaq debut that could funnel fresh cash into its neuropsychiatric drug pipeline. Spun out of PureTech’s R&D operation, the company is pitching investors on its proprietary “Glyph” prodrug platform, which is designed to improve oral delivery for proven central nervous system mechanisms. Around Boston’s lab clusters, the quiet question is whether Seaport’s private momentum and development timeline can translate into a successful run on the public markets.
Local reporting
As reported by Boston Business Journal, Seaport’s IPO filing lands in the middle of a year when several Boston life science companies are again edging toward the public markets. The outlet notes that Zohar is at the helm and frames the move as one more data point in a cautious but noticeable pickup in IPO activity around the region.
Deal size and bookrunners
Market trackers say Seaport is seeking to raise up to $100 million and has lined up Goldman Sachs, J.P. Morgan, Leerink Partners, Citi and Stifel as joint bookrunners. Renaissance Capital summarizes the offering and notes that the company initially filed confidentially in November 2025 before shifting to a public filing this spring.
What the S-1 shows
The registration statement filed with the SEC on Friday lists Seaport’s principal executive offices at 101 Seaport Blvd., Floor 12, in Boston and confirms the proposed Nasdaq ticker symbol "SPTX." The SEC filing also lays out the Glyph platform and states that proceeds are earmarked to advance lead candidates GlyphAllo (SPT-300), which is in a Phase 2b BUOY-1 trial, and GlyphAgo (SPT-320), which reported Phase 1 pharmacokinetic data this month.
Background and origin
Seaport was spun out of PureTech and launched with a $100 million Series A in April 2024, with PureTech retaining a sizable stake while transferring Glyph intellectual property into the new venture. A Business Wire release details Zohar’s move from PureTech to lead Seaport and highlights the hub and spoke strategy that previously produced companies such as Karuna.
Why it matters for Boston
The filing arrives during what looks like a tentative thaw in the biotech IPO market, after a stretch of chillier conditions. Trade outlets have pointed to a recent trickle of S-1 filings by Boston area companies as a sign that public windows for life science deals might be reopening. GEN and other publications have tracked several 2026 offerings, suggesting investor appetite is slowly creeping back into the sector.
Next steps
For now, Seaport’s prospectus is still preliminary. Exact share counts, pricing ranges and the timing of any debut will be set by the underwriting syndicate and will hinge on market conditions. The company says it intends to deliver shares "as soon as practicable" after the registration statement becomes effective, so the next things to watch are the initial price range and whether investor demand for neuropsychiatric programs is strong enough to keep the deal on course.
